Grant: CIHR Fellowship
McMaster University
$135,000.00
Investigating Macrophage AMPK as a Potential Therapeutic Target for Treating Type 2 Diabetes and Cardiovascular Disease
EF 2019-20
Résumé
Rates of Type 2 Diabetes and cardiovascular disease are rapidly increasing in Canada. These conditions often occur together and evidence suggests that they should also be treated together. Unfortunately, current therapies for either condition are ineffective. We believe that the high blood glucose that occurs during the development of type 2 diabetes causes inflammation, which represents the key link between diabetes and CVD. Specifically, macrophages, a type of immune cell, are essential mediators of the inflammation present in diabetes and CVD. Moreover, we have evidence suggesting that activating an enzyme called "AMPK" in macrophages may reduce inflammation and improve symptoms associated with diabetes and CVD. To test this, we will directly expose macrophages to high amounts of glucose and assess the inflammation that develops. We will also directly treat macrophages with a newly developed drug to activate AMPK to see if we can reduce inflammation in macrophages in the presence of high glucose. We will also treat mice with this AMPK activating drug and assess whether AMPK is activated in macrophages and whether this can prevent the development of diabetes and CVD in lean and obese mice with high blood glucose. Finally, we have previously tracked the development of diabetes and CVD in ~1400 humans, and we will use these data together with the current experiments to try and uncover a new marker that can be used to predict the development of diabetes and CVD in humans. Together, these results will provide extremely important evidence on the development of Type 2 Diabetes and CVD and new therapeutic ways of predicting, preventing, and treating these conditions.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
412759
Name
Townsend Logan K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Investigating Macrophage AMPK as a Potential Therapeutic Target for Treating Type 2 Diabetes and Cardiovascular Disease
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Ampk; Atherosclerosis; Diabetes; Inflammation
Abstract
Rates of Type 2 Diabetes and cardiovascular disease are rapidly increasing in Canada. These conditions often occur together and evidence suggests that they should also be treated together. Unfortunately, current therapies for either condition are ineffective. We believe that the high blood glucose that occurs during the development of type 2 diabetes causes inflammation, which represents the key link between diabetes and CVD. Specifically, macrophages, a type of immune cell, are essential mediators of the inflammation present in diabetes and CVD. Moreover, we have evidence suggesting that activating an enzyme called "AMPK" in macrophages may reduce inflammation and improve symptoms associated with diabetes and CVD. To test this, we will directly expose macrophages to high amounts of glucose and assess the inflammation that develops. We will also directly treat macrophages with a newly developed drug to activate AMPK to see if we can reduce inflammation in macrophages in the presence of high glucose. We will also treat mice with this AMPK activating drug and assess whether AMPK is activated in macrophages and whether this can prevent the development of diabetes and CVD in lean and obese mice with high blood glucose. Finally, we have previously tracked the development of diabetes and CVD in ~1400 humans, and we will use these data together with the current experiments to try and uncover a new marker that can be used to predict the development of diabetes and CVD in humans. Together, these results will provide extremely important evidence on the development of Type 2 Diabetes and CVD and new therapeutic ways of predicting, preventing, and treating these conditions.
Competitiondate
201910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Townsend, Logan K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~